Biopharmaceutical

Twist Bioscience to Expand Oregon Lease, Supporting Future Growth

Friday, April 16, 2021 - 1:00pm

\xe2\x80\x9cWe need to plan for space about 18 to 24 months in the future.

Key Points: 
  • \xe2\x80\x9cWe need to plan for space about 18 to 24 months in the future.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\nThis press release contains forward-looking statements.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005020/en/\n'

SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders

Thursday, April 15, 2021 - 7:11pm

FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.

Key Points: 
  • FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer.
  • On February 11, 2020, FibroGen announced that the FDA had completed its filing review of its NDA for roxadustat.
  • FibroGen acknowledged that it could no longer conclude that roxadustat reduces the risk of cardiovascular events or hospitalization when compared to a currently approved anemia injection used as a control.
  • Shareholders pay no fees or expenses.\nContact us to learn more:\n'

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

Thursday, April 15, 2021 - 1:00pm

b'Tallac Therapeutics, Inc. (\xe2\x80\x9cTallac\xe2\x80\x9d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer\n\xe2\x80\x9cWe are delighted to welcome Curtis to Tallac.

Key Points: 
  • b'Tallac Therapeutics, Inc. (\xe2\x80\x9cTallac\xe2\x80\x9d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer\n\xe2\x80\x9cWe are delighted to welcome Curtis to Tallac.
  • Curtis\xe2\x80\x99s extensive industry experience spearheading research and development collaborations and partnerships will be invaluable to Tallac as we advance multiple assets from our novel TRAAC platform,\xe2\x80\x9d said Hong I. Wan, Ph.D., President, Chief Executive Officer and co-founder of Tallac.\nCurtis Hecht joins the company with over 25 years of leadership, corporate strategy and business development experience, most recently from Calithera Biosciences, Inc. where he served as Chief Business Officer.
  • Previously, Curtis held senior business development roles at various life sciences and biotechnology companies including DNA Ink, inVentiv Health, Genentech and Roche.
  • \xe2\x80\x9cI\xe2\x80\x99m excited at the opportunity to work with the exceptional team at Tallac during this pivotal phase of its growth.\xe2\x80\x9d\nTallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.

Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C

Thursday, April 15, 2021 - 2:30pm

With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.

Key Points: 
  • With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.
  • With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries.
  • www.aceto.com\nA&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients (APIs).
  • A&C is committed to providing certified GMP products in full compliance with international regulatory requirements to meet customers\xe2\x80\x99 needs globally.\n"

Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies

Thursday, April 15, 2021 - 12:00pm

b'Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has raised $80 million in a Series A financing.

Key Points: 
  • b'Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has raised $80 million in a Series A financing.
  • Tectonic\xe2\x80\x99s mission is to unlock the full potential of GPCR-targeted therapies with biologics.
  • His research enabled the discovery of several important medicines including Campath\xc2\xae, Velcade\xc2\xae, and Entyvio\xc2\xae.
  • The Tectonic platform makes it possible to develop a broad pipeline of biologics against the most challenging receptors in the class.

Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit

Thursday, April 15, 2021 - 1:00pm

b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.

Key Points: 
  • b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.
  • The summit is a virtual event and the presentation will be accessible to conference registrants for 30 days.\nAxial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-targeted, small molecule therapeutics to treat neurological conditions and cancer.
  • Axial is advancing a pipeline of product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson\xe2\x80\x99s Disease (PD).
  • For more information, visit https://axialtx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005085/en/\n'

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

Wednesday, April 14, 2021 - 1:00pm

Certain libraries among the portfolio are deliberately tailored to match chosen classes of biological targets as well as to enhance bispecific antibody forming capabilities.

Key Points: 
  • Certain libraries among the portfolio are deliberately tailored to match chosen classes of biological targets as well as to enhance bispecific antibody forming capabilities.
  • Together, the companies will work to discover, validate and optimize new antibody candidates against targets useful for immuno-oncology applications.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\nThis press release contains forward-looking statements.

SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company

Wednesday, April 14, 2021 - 12:00pm

b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.

Key Points: 
  • b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.
  • Lilly will receive an upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro.
  • Lilly retains all rights outside Greater China.\n\xe2\x80\x9cApproximately 3 million elderly people are currently affected by Parkinson\xe2\x80\x99s disease in Greater China, creating a significant disease burden.
  • Located in the major life sciences hubs of Shanghai and Philadelphia, SciNeuro is establishing a robust CNS product pipeline through internal innovation and global partnerships.

Outlook on the Pharmaceutical Drugs and Biologics Logistics Global Market to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Tuesday, April 13, 2021 - 1:06pm

The top opportunities in the pharmaceutical drugs and biologics logistics market segmented by mode of transport will arise in the land transportation segment, which will gain $7,161.7 million of global annual sales by 2025.

Key Points: 
  • The top opportunities in the pharmaceutical drugs and biologics logistics market segmented by mode of transport will arise in the land transportation segment, which will gain $7,161.7 million of global annual sales by 2025.
  • The top opportunities in the pharmaceutical drugs and biologics logistics market segmented by pharmaceutical type will arise in the pharmaceutical drugs segment, which will gain $8,597.0 million of global annual sales by 2025.
  • The top opportunities in the pharmaceutical drugs and biologics logistics market segmented by therapeutic are will arise in the metabolic disorders drugs segment.\nMarket-trend-based strategies for the pharmaceutical drugs and biologics logistics market include acquiring new technologies and expertise, providing sea-based logistics services, focusing on patient-centric supply chains, using automated storage and retrieval systems, adopting advanced digital technologies, investing in reusable packaging, phase change materials, focusing on energy efficiency, and focusing on green supply chain management.
  • Player-adopted strategies in the pharmaceutical drugs and biologics logistics market include expanding through strategic partnerships, and expanding through investing in building warehouses in different geographies.\nTo take advantage of the opportunities, the publisher recommends the pharmaceutical drugs and biologics logistics market companies to focus on acquiring companies, patient-centric supply chains, digitalization, investing in green supply chain management, expanding in emerging markets, provide competitively priced offerings, leverage social media, targeting distributors in emerging markets and collaboration with e-commerce companies.\n'

Zymeworks to Present at Bloom Burton Healthcare Conference

Tuesday, April 13, 2021 - 1:30pm

Zymeworks\xe2\x80\x99 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

Key Points: 
  • Zymeworks\xe2\x80\x99 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
  • Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.
  • In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
  • For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005077/en/\n'